In today’s session Amgen, Inc. (AMGN) registered an unusually high (779) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the December, 2016 call, expecting serious AMGN increase. With 779 contracts traded and 1364 open interest for the Dec, 16 contract, it seems this is a quite bullish bet. The option with symbol: AMGN161216C00146000 closed last at: $2.8 or 17.2% up. About 475,514 shares traded hands. Amgen, Inc. (NASDAQ:AMGN) has declined 10.27% since April 28, 2016 and is downtrending. It has underperformed by 16.20% the S&P500.
Analysts await Amgen, Inc. (NASDAQ:AMGN) to report earnings on January, 26. They expect $2.77 EPS, up 6.13% or $0.16 from last year’s $2.61 per share. AMGN’s profit will be $2.03B for 12.97 P/E if the $2.77 EPS becomes a reality. After $3.02 actual EPS reported by Amgen, Inc. for the previous quarter, Wall Street now forecasts -8.28% negative EPS growth.
Amgen, Inc. (NASDAQ:AMGN) Ratings Coverage
Out of 17 analysts covering Amgen Inc. (NASDAQ:AMGN), 10 rate it a “Buy”, 0 “Sell”, while 7 “Hold”. This means 59% are positive. $218 is the highest target while $160 is the lowest. The $187.39 average target is 30.42% above today’s ($143.68) stock price. Amgen Inc. has been the topic of 29 analyst reports since August 3, 2015 according to StockzIntelligence Inc. The firm earned “Overweight” rating on Saturday, August 29 by Piper Jaffray. UBS upgraded Amgen, Inc. (NASDAQ:AMGN) rating on Monday, September 7. UBS has “Buy” rating and $168 price target. The rating was initiated by Leerink Swann on Friday, February 5 with “Market Perform”. The firm has “Buy” rating given on Friday, August 21 by Vetr. Gabelli initiated the shares of AMGN in a report on Friday, August 26 with “Hold” rating. Deutsche Bank maintained Amgen, Inc. (NASDAQ:AMGN) rating on Friday, July 31. Deutsche Bank has “Buy” rating and $195 price target. The company was initiated on Friday, December 4 by Wells Fargo. The firm has “Overweight” rating by Piper Jaffray given on Thursday, November 5. Argus Research maintained Amgen, Inc. (NASDAQ:AMGN) rating on Monday, February 8. Argus Research has “Buy” rating and $185 price target. RBC Capital Markets maintained it with “Outperform” rating and $190 target price in Friday, July 31 report.
According to Zacks Investment Research, “Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new science’s promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people’s lives.”
Insitutional Activity: The institutional sentiment decreased to 1.26 in Q2 2016. Its down 0.02, from 1.28 in 2016Q1. The ratio dropped, as 56 funds sold all Amgen, Inc. shares owned while 422 reduced positions. 77 funds bought stakes while 533 increased positions. They now own 577.82 million shares or 7.76% less from 626.39 million shares in 2016Q1.
Beck Mack Oliver Limited Com holds 0.06% of its portfolio in Amgen, Inc. (NASDAQ:AMGN) for 12,100 shares. Tctc Ltd accumulated 28,899 shares or 0.3% of the stock. Tanaka Cap Management Inc, a New York-based fund reported 3,368 shares. Dumont & Blake Inv Advisors Lc reported 10,960 shares or 0.85% of all its holdings. Twin Tree Mgmt Lp last reported 10,065 shares in the company. Moreover, Lba Wealth Management Ltd Liability has 0.07% invested in Amgen, Inc. (NASDAQ:AMGN) for 778 shares. Springbok Capital Limited Liability holds 0.04% of its portfolio in Amgen, Inc. (NASDAQ:AMGN) for 2,044 shares. Moreover, Bingham Osborn Scarborough Limited Co has 0.05% invested in Amgen, Inc. (NASDAQ:AMGN) for 2,705 shares. Ronald Blue & Limited Liability Corp accumulated 1,460 shares or 0.01% of the stock. Ahl Partners Ltd Liability Partnership, a United Kingdom-based fund reported 6,333 shares. Mesirow Finance Inv Mngmt has 0.03% invested in the company for 2,821 shares. Scotia Cap Inc has 0.02% invested in the company for 6,933 shares. Papp L Roy And Assoc accumulated 0.31% or 8,520 shares. Capital Advisory Services has 0.1% invested in the company for 3,589 shares. Armstrong Shaw Ct last reported 68,549 shares in the company.
Insider Transactions: Since August 1, 2016, the stock had 0 buys, and 1 sale for $523,758 net activity. Such Annette Louise sold $523,758 worth of stock or 3,000 shares.
Amgen Inc. is a biotechnology company. The company has a market cap of $105.47 billion. The Firm discovers, develops, makes and delivers various human therapeutics. It has a 14.35 P/E ratio. The Company’s business segment is human therapeutics.
AMGN Company Profile
Amgen Inc., incorporated on October 31, 1986, is a biotechnology company. The Firm discovers, develops, makes and delivers various human therapeutics. The Company’s business segment is human therapeutics. The Company’s marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine). The Firm focuses its research and development on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.
More recent Amgen, Inc. (NASDAQ:AMGN) news were published by: Fool.com which released: “Better Buy: Amgen Inc. vs. Johnson & Johnson” on November 08, 2016. Also Fool.com published the news titled: “Why Amgen Inc. Shares Nose-Dived 15.4% in October” on November 08, 2016. Investorplace.com‘s news article titled: “3 Stocks to Watch on Wednesday: Amgen, Inc. (AMGN), Cisco Systems, Inc. (CSCO …” with publication date: November 17, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.